Results 141 to 150 of about 121,521 (304)

Pramipexole Upregulates Dopamine Receptor D2 and D3 Expression in Rat Striatum

open access: yesJournal of Pharmacological Sciences, 2012
Randomized clinical trials have shown that pramipexole has an antidepressant effect in patients with Parkinson’s disease. We investigated the comparative efficacy of pramipexole toward dopamine receptor D2 and D3 expression in rat brain.
Naohito Tokunaga   +7 more
doaj  

Schizophrenia: Normal Sequence in the Dopamine D2 Receptor Region that Couples to G-Proteins. DNA Polymorphisms in D2 [PDF]

open access: bronze, 1993
Philip Seeman   +6 more
openalex   +1 more source

Progress on the development of Class A GPCR‐biased ligands

open access: yesBritish Journal of Pharmacology, EarlyView.
Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales   +20 more
wiley   +1 more source

Molecular De Novo Design through Deep Reinforcement Learning [PDF]

open access: yesarXiv, 2017
This work introduces a method to tune a sequence-based generative model for molecular de novo design that through augmented episodic likelihood can learn to generate structures with certain specified desirable properties. We demonstrate how this model can execute a range of tasks such as generating analogues to a query structure and generating ...
arxiv  

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

open access: yesBritish Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander   +5 more
wiley   +1 more source

ESG‐1‐60 and ESG‐1‐61: Novel dopamine D3 receptor‐preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Preclinical studies suggest that highly selective dopamine D3 receptor (D3R) antagonists or partial agonists hold promise for treating substance use disorders. However, their limited effectiveness in reducing cocaine self‐administration is a major drawback.
Omar Soler‐Cedeño   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy